4′-hydroxywogonin inhibits oral squamous cell carcinoma progression by targeting Gas6/Axl signaling axis
4'-Hydroxywogonin exhibits potential as a novel therapeutic agent for OSCC, with the capacity to enhance cisplatin-mediated anticancer effects, highlighting its potential in combination therapy.
Authors
- Li‐Fang Chou (ORCID: https://orcid.org/0000-0002-0189-1699)
- K.-N. Chen
- Tong‐Hong Wang (ORCID: https://orcid.org/0000-0001-9248-9031)
- Yu‐De Chu (ORCID: https://orcid.org/0000-0002-5496-8573)
- Yi-Tsen Liu
- Chih‐Cheng Chen (ORCID: https://orcid.org/0000-0002-8938-3209)
- Hsin-Wei Lin
- Chau‐Ting Yeh
- Cheng-Chia Yu
Institutions
- Chang Gung University of Science and Technology (TW)
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Taoyuan Chang Gung Memorial Hospital (TW)
- Chung Shan Medical University Hospital (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Journal of Dental Sciences
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1016/j.jds.2025.03.012
- Citations
- 2
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Chang Gung Memorial Hospital
- National Science Council
- Chang Gung Medical Foundation